Pancreatic Tubular Adenocarcinoma Clinical Trial
— GEMSTHEROfficial title:
Observational Study - Influence of Gemcitabine Treatment on Immunological and Serological Profile in Patients With Pancreatic Tubular Carcinoma
Observational study of influence of gemcitabine treatment on serological and immunological status and gene expression profile in patients with pancreatic tubular carcinoma after tumor resection.
Status | Recruiting |
Enrollment | 0 |
Est. completion date | December 2011 |
Est. primary completion date | December 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 30 Years to 85 Years |
Eligibility |
Inclusion Criteria: - ECOG performance status 0-2 at the time of inclusion - Following R0 or R1 pancreatic tubular adenocarcinoma resection Exclusion Criteria: - Pregnancy - Serious comorbidity |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Slovenia | University Medical Centre Ljubljana; Department for Gastroenterology | Ljubljana |
Lead Sponsor | Collaborator |
---|---|
Blood Transfusion Centre of Slovenia | University Medical Centre Ljubljana |
Slovenia,
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01021800 -
Modulation of the Immune Response in Patients With Pancreatic Tubular Adenocarcinoma
|
Phase 2 |